About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 847670, 6 pages
http://dx.doi.org/10.1155/2013/847670
Research Article

Abnormal Nerve Conduction Study Findings Indicating the Existence of Peripheral Neuropathy in Multiple Sclerosis and Neuromyelitis Optica

Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai Fuchu, Tokyo 183-0042, Japan

Received 23 April 2013; Accepted 21 September 2013

Academic Editor: Michael Mahler

Copyright © 2013 Yoko Warabi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Sarova-Pinhas, A. Achiron, R. Gilad, and Y. Lampl, “Peripheral neuropathy in multiple sclerosis: a clinical and electrophysiologic study,” Acta Neurologica Scandinavica, vol. 91, no. 4, pp. 234–238, 1995. View at Scopus
  2. S. Misawa, S. Kuwabara, M. Mori, S. Hayakawa, S. Sawai, and T. Hattori, “Peripheral nerve demyelination in multiple sclerosis,” Clinical Neurophysiology, vol. 119, no. 8, pp. 1829–1833, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Kamm and U. K. Zettl, “Autoimmune disorders affecting both the central and peripheral nervous system,” Autoimmunity Reviews, vol. 11, no. 3, pp. 196–202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Fukazawa, S. Kikuchi, R. Miyagishi et al., “CSF pleocytosis and expansion of spinal lesions in Japanese Multiple sclerosis with special reference to the new diagnostic criteria,” Journal of Neurology, vol. 252, no. 7, pp. 824–829, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. V. A. Lennon, T. J. Kryzer, S. J. Pittock, A. S. Verkman, and S. R. Hinson, “IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel,” Journal of Experimental Medicine, vol. 202, no. 4, pp. 473–477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Misu, K. Fujihara, A. Kakita et al., “Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis,” Brain, vol. 130, no. 5, pp. 1224–1234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Aimoto, K. Ito, F. Moriwaka, K. Tashiro, and K. Abe, “Demyelinating peripheral neuropathy in Devic disease,” Japanese Journal of Psychiatry and Neurology, vol. 45, no. 4, pp. 861–864, 1991. View at Scopus
  8. M. Kitada, H. Suzuki, J. Ichihashi, R. Inada, K. Miyamoto, T. Takahashi, et al., “Acute combined central and peripheral demyelination showing anti-aquaporin 4 antibody positivity,” Internal Medicine, vol. 51, pp. 2443–2447, 2012.
  9. Y. Warabi, K. Yagi, and H. Hayashi, “Multiple sclerosis in Tokyo Metropolitan Neurological Hospital: from the view points of north latitude and Japan's rapid economic growth,” Clinical Neurology, vol. 43, no. 7, pp. 432–433, 2003. View at Scopus
  10. C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Wingerchuk, V. A. Lennon, S. J. Pittock, C. F. Lucchinetti, and B. G. Weinshenker, “Revised diagnostic criteria for neuromyelitis optica,” Neurology, vol. 66, no. 10, pp. 1485–1489, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. D. M. Wingerchuk, V. A. Lennon, C. F. Lucchinetti, S. J. Pittock, and B. G. Weinshenker, “The spectrum of neuromyelitis optica,” The Lancet Neurology, vol. 6, no. 9, pp. 805–815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Y. Van den Bergh, R. D. Hadden, P. Bouche et al., “European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society: first Revision,” Journal of the Peripheral Nervous System, vol. 15, no. 1, pp. 1–9, 2010. View at Publisher · View at Google Scholar
  14. K. Ota, M. Matsui, E. L. Milford, G. A. Mackin, H. L. Weiner, and D. A. Hafler, “T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis,” Nature, vol. 346, no. 6280, pp. 183–187, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Pette, K. Fujita, D. Wilkinson et al., “Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 20, pp. 7968–7972, 1990. View at Scopus
  16. R. A. C. Hughes, D. Allen, A. Makowska, and N. A. Gregson, “Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy,” Journal of the Peripheral Nervous System, vol. 11, no. 1, pp. 30–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. B. C. Kieseier, M. C. Dalakas, and H.-P. Hartung, “Immune mechanisms in chronic inflammatory demyelinating neuropathy,” Neurology, vol. 59, no. 12, pp. S7–S12, 2002. View at Scopus
  18. M. Falcone, A. Scalise, C. Minisci, D. Romito, I. Cancelli, and G. L. Gigli, “Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy,” Neurological Sciences, vol. 27, no. 1, pp. 58–62, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Scopus
  20. Y. Warabi, K. Yagi, H. Hayashi, and Y. Matsumoto, “Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is up-regulated compared to multiple sclerosis,” Journal of the Neurological Sciences, vol. 249, no. 2, pp. 145–152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. B. T. Sadatipour, J. M. Greer, and M. P. Pender, “Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis,” Annals of Neurology, vol. 44, no. 6, pp. 980–983, 1998. View at Scopus
  22. R. Srivastava, M. Aslam, S. R. Kalluri, L. Schirmer, D. Buck, B. Tackenberg, et al., “Potassium channel KIR4. 1 as an immune target in multiple sclerosis,” The New England Journal of Medicine, vol. 367, pp. 115–123, 2012.
  23. T. Berger, P. Rubner, F. Schautzer et al., “Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event,” The New England Journal of Medicine, vol. 349, no. 2, pp. 139–145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. P. R. Burton, D. G. Clayton, L. R. Cardon et al., “Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls,” Nature, vol. 447, no. 7145, pp. 661–678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium, S. Sawcer, G. Hellenthal, M. Pirinen, C. C. Spencer, et al., “Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis,” Nature, vol. 476, pp. 214–219, 2011.
  26. N. A. Sutedja, H. G. Otten, E. A. Cats et al., “Increased frequency of HLA-DRB1*15 in patients with multifocal motor neuropathy,” Neurology, vol. 74, no. 10, pp. 828–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Gironi, F. R. Guerini, E. Beghi et al., “HLA-DRB1 polymorphisms distribution in chronic dysimmune polyneuropathy,” Neuromuscular Disorders, vol. 18, no. 12, pp. 967–969, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Ekstein, E. Linetsky, O. Abramsky, and D. Karussis, “Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis,” Neurology, vol. 65, no. 3, pp. 456–458, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Pirko, N. L. Kuntz, M. Patterson, B. M. Keegan, B. G. Weinshenker, and M. Rodriguez, “Contrasting effects of IFNβ and IVIG in children with central and peripheral demyelination,” Neurology, vol. 60, no. 10, pp. 1697–1699, 2003. View at Scopus
  30. D. Matsuse, H. Ochi, K. Tashiro et al., “Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonβ-1b therapy in a patient with childhood-onset multiple sclerosis,” Internal Medicine, vol. 44, no. 1, pp. 68–72, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Aronovich, A. Katzav, and J. Chapman, “The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally,” Clinical Reviews in Allergy and Immunology, vol. 42, pp. 181–188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Motta, A. Golba, M. Huc, and Z. Kazibutowska, “Development of Guillain-Barre syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate,” Polish Journal of Neurology and Neurosurgery, vol. 46, pp. 189–191, 2012.
  33. T. Yonekawa, T. Matsushita, M. Minohara et al., “T cell reactivities to myelin protein-derived peptides in neuromyelitis optica patients with anti-aquaporin-4 antibody,” Neurology Asia, vol. 16, no. 2, pp. 139–142, 2011. View at Scopus
  34. N. Matsuya, M. Komori, K. Nomura et al., “Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica,” International Immunology, vol. 23, no. 9, pp. 565–573, 2011. View at Publisher · View at Google Scholar · View at Scopus